PCM
WVE icon

Prelude Capital Management’s Wave Life Sciences WVE Stock Holding History

Prelude Capital Management’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,600
Closed -$17K – 2422
2020
Q2 		$17K Buy
+1,600
New +$15.1K ﹤0.01% 1428
2020
Q1 		– Sell
-1,200
Closed -$10K – 2103
2019
Q4 		$10K Buy
+1,200
New +$29.4K ﹤0.01% 1711

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Prelude Capital Management's WVE Position: Q1 2026 in Review

Prelude Capital Management sold out of Wave Life Sciences (WVE) in Q1 2026, closing a stake of 93,202 shares — an estimated $1.58M sold.

Prelude Capital Management first reported a position in WVE in Q4 2020 and held it in 6 quarters. The position peaked at $1.58M in Q4 2025. 230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Prelude Capital Management reported no remaining Wave Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 93,202 Wave Life Sciences shares in Q1 2026, an estimated $1.58M.
  • Prelude Capital Management first reported a position in Wave Life Sciences in Q4 2020 and held it in 6 quarters.
  • Prelude Capital Management's Wave Life Sciences position peaked at $1.58M in Q4 2025.
  • 230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.